New lung cancer drug challenges standard treatment in major trial
NCT ID NCT07360132
Summary
This study compares a new drug combination (HB0025 plus chemotherapy) against the current standard treatment (pembrolizumab plus chemotherapy) for people with advanced squamous non-small cell lung cancer who haven't had prior treatment. About 480 participants will be randomly assigned to receive one of the two drug combinations, followed by maintenance therapy. The main goal is to see which treatment better delays cancer progression while monitoring safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The East Hospital Affiliated to Tongji University
Shanghai, Shanghai Municipality, 200120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.